Tag Archives: Market Access
By Guest Blogger | Published: September 20, 2013
by John Glasspool Paradigms change when questions emerge the old paradigm can no longer answer. Market access has become a buzz word as access to markets is as significant a hurdle to product usage as registration itself. Initially a topic for pharmaceutical companies concerned about volume, it now affects all aspects of healthcare. We believe […]
By Ben Comer | Published: February 5, 2013
Good science can’t be rushed, even when the lives of patients hang in the balance. But regulatory science, and its relationship to a drug’s commercial success or failure, can inadvertently block access to individual patients in their hour of need.
By Ben Comer | Published: October 17, 2011
Last year, only two percent of the respondents surveyed by Cegedim cited regulatory and compliance issues as a driver of new technology adoption, and six percent said regulatory and compliance was a primary driver of pharmaceutical business model or process change. A lot can happen in a year.
By Julian Upton | Published: January 17, 2011
His decade-long tenure as head of the European Medicines Agency (EMA) may have ended, but Thomas Lönngren is already back in the regulatory saddle as a strategic advisor to NDA Group, an independent consulting group focused on reducing wasted drug development costs, ensuring new medicines get to market faster, and “improving the performance of the […]
By William Looney | Published: January 5, 2011
Building a durable base for growth in emerging markets is top line in pharma’s strategy to compensate for slowing sales in the US and Europe. Key to success is moving beyond the traditional reliance on serving the smallest, most affluent segment of the market to seed critical mass: expanding resources for health, broadening the customer […]